Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen

<strong>Objective: <br></strong> Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir with an optimized nucleoside reverse transcriptase inhibitor (NRTI) backbone. We...

Descripció completa

Dades bibliogràfiques
Autors principals:	Keene, CM, Griesel, R, Zhao, Y, Gcwabe, Z, Sayed, K, Hill, A, Cassidy, T, Ngwenya, O, Jackson, A, van Zyl, G, Schutz, C, Goliath, R, Flowers, T, Goemaere, E, Wiesner, L, Simmons, B, Maartens, G, Meintjes, G
Format:	Journal article
Idioma:	English
Publicat:	Lippincott, Williams and Wilkins 2021

Ítems similars

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
per: Zhao, Y, et al.
Publicat: (2021)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
per: Keene, CM, et al.
Publicat: (2023)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
per: Rhee, S, et al.
Publicat: (2017)

Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
per: Zhao, Y, et al.
Publicat: (2023)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
per: Dorward, J, et al.
Publicat: (2023)

Media reporting of tenofovir trials in Cambodia and Cameroon
Publicat: (2005)

Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
per: Wainwright, E, et al.
Publicat: (2013)

Tenofovir for children and adults with chronic hepatitis B
per: Li, Huijuan, et al.
Publicat: (2023)

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study
per: Asare, K, et al.
Publicat: (2023)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
per: Griesel, R, et al.
Publicat: (2023)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
per: Shaik Ismail, Siti Mahanim
Publicat: (2015)

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy
per: Dorward, J, et al.
Publicat: (2023)

Di- tert -butyl Phosphonate Route to the Antiviral Drug Tenofovir
per: Dietz, Jule-Philipp, et al.
Publicat: (2022)

Cost–utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
per: Dakin, H, et al.
Publicat: (2011)

Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
per: McCormick, A, et al.
Publicat: (2010)

Hypophosphataemia in HIV-positive patients taking non-tenofovir-containing antiretrovirals
per: Wainwright, E, et al.
Publicat: (2011)

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
per: Green, H, et al.
Publicat: (2007)

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
per: Archary, D, et al.
Publicat: (2017)

Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV observational Database
per: Zhou, J., et al.
Publicat: (2007)

Does tenofovir-containing first-line antiretroviral therapy mitigate the impact of pretreatment non-nucleoside reverse transcriptase inhibitor drug resistance?
per: Inzaule, SC, et al.
Publicat: (2018)

Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study
per: Chen, Jianmeng, et al.
Publicat: (2014)

Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: A systematic review
per: Bierhoff, M, et al.
Publicat: (2019)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
per: Ho, Sharlene, et al.
Publicat: (2021)

Is the risk of tenofovir-induced nephrotoxicity similar in treatment-naïve compared to treatment-experienced patients?
per: Low, Joo Zheng, et al.
Publicat: (2018)

Selective Lewis Acid Catalyzed Assembly of Phosphonomethyl Ethers: Three-Step Synthesis of Tenofovir
per: Ocampo, Charles Edward, et al.
Publicat: (2016)

Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy
per: Lui, Y.Y.N., et al.
Publicat: (2010)

Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue
per: Louissaint, Nicolette A., et al.
Publicat: (2015)

Atorvastatin rapidly reduces hepatitis B viral load in combination with Tenofovir: a prospective clinical trial
per: Gharehbeglou, M., et al.
Publicat: (2022)

Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
per: Fux, C, et al.
Publicat: (2007)

Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase
per: Drosu, Natalia C, et al.
Publicat: (2021)

Tenofovir disoproxil fumarate fails to prevent HIV acquisition or the establishment of a viral reservoir: two case reports
per: Fox, J, et al.
Publicat: (2016)

Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
per: Boothby, M, et al.
Publicat: (2009)

Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy
per: McGee, K, et al.
Publicat: (2009)

Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: an observational case series of South African adults
per: Mokaya, J, et al.
Publicat: (2020)

Challenges of implementing tenofovir disoproxil fumarate in pregnancy for prevention of hepatitis B mother to child transmission in a rural population
per: Bierhoff, M, et al.
Publicat: (2020)

Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
per: Dakin, H, et al.
Publicat: (2011)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
per: Gibb, D, et al.
Publicat: (2012)

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective.
per: Dakin, H, et al.
Publicat: (2011)

Tenofovir prophylaxis during pregnancy for the elimination of mother-to-child transmission of hepatitis B virus: a cost-effectiveness analysis
per: Janekrongtham, C, et al.
Publicat: (2023)

Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa
per: Mokaya, J, et al.
Publicat: (2019)